A translational framework to DELIVER nanomedicines to the clinic.

Autor: Joyce P; Centre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia. paul.joyce@unisa.edu.au., Allen CJ; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada., Alonso MJ; Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), IDIS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Ashford M; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK., Bradbury MS; Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medical College, New York, NY, USA., Germain M; Curadigm, Nanobiotix, Paris, France., Kavallaris M; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, Faculty of Medicine and Health UNSW, Sydney, New South Wales, Australia.; UNSW Australian Centre for Nanomedicine, Faculty of Engineering, University of New South Wales (UNSW), Sydney, New South Wales, Australia., Langer R; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Lammers T; Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Hospital, Aachen, Germany.; Mildred Scheel School of Oncology (MSSO), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIOABCD), RWTH Aachen University Hospital, Aachen, Germany., Peracchia MT; mRNA Center of Excellence, Sanofi R&D, Marcy l'Etoile, France., Popat A; School of Pharmacy, The University of Queensland, Woolloongabba, Queensland, Australia., Prestidge CA; Centre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia., Rijcken CJF; Cristal Therapeutics, Maastricht, The Netherlands., Sarmento B; IiS - Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.; INEB - Institute for Biomedical Engineering, University of Porto, Porto, Portugal., Schmid RB; Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway., Schroeder A; The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa, Israel., Subramaniam S; Centre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia., Thorn CR; BioTherapeutics Pharmaceutical Sciences, Pfizer, Andover, MA, USA., Whitehead KA; Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA, USA., Zhao CX; School of Chemical Engineering, Faculty of Sciences, Engineering and Technology, University of Adelaide, Adelaide, South Australia, Australia.; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia., Santos HA; Department of Biomaterials and Biomedical Technology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. h.a.santos@umcg.nl.; The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, Groningen, The Netherlands. h.a.santos@umcg.nl.; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. h.a.santos@umcg.nl.

Publikováno v: Nature nanotechnology [Nat Nanotechnol] 2024 Nov; Vol. 19 (11), pp. 1597-1611. Date of Electronic Publication: 2024 Sep 06.

The journey of a lifetime - development of Pfizer's COVID-19 vaccine.

Autor: Thorn CR; Pharmaceutical Research and Development, Biotherapeutics Pharm Sci, Pfizer Inc., USA., Sharma D; Pharmaceutical Research and Development, Biotherapeutics Pharm Sci, Pfizer Inc., USA., Combs R; Bioprocess Research and Development, Biotherapeutics Pharm Sci, Pfizer Inc., USA., Bhujbal S; Pharmaceutical Research and Development, Biotherapeutics Pharm Sci, Pfizer Inc., USA., Romine J; Bioprocess Research and Development, Biotherapeutics Pharm Sci, Pfizer Inc., USA., Zheng X; Bioprocess Research and Development, Biotherapeutics Pharm Sci, Pfizer Inc., USA., Sunasara K; Bioprocess Research and Development, Biotherapeutics Pharm Sci, Pfizer Inc., USA., Badkar A; Pharmaceutical Research and Development, Biotherapeutics Pharm Sci, Pfizer Inc., USA. Electronic address: advait.v.badkar@pfizer.com.

Publikováno v: Current opinion in biotechnology [Curr Opin Biotechnol] 2022 Dec; Vol. 78, pp. 102803. Date of Electronic Publication: 2022 Sep 01.

Liquid Crystal Nanoparticles Enhance Tobramycin Efficacy in a Murine Model of Pseudomonas aeruginosa Biofilm Wound Infection.

Autor: Thorn CR; University of South Australia, Clinical and Health Science, North Tce, Adelaide, SA 5000, Australia.; The Basil Hetzel Institute for Translational Health Research, Woodville, SA 5011, Australia.; Biofilm Test Facility, Cancer Research Institute, University of South Australia, North Tce, Adelaide, SA 5000, Australia., Wignall A; University of South Australia, Clinical and Health Science, North Tce, Adelaide, SA 5000, Australia., Kopecki Z; University of South Australia, Clinical and Health Science, North Tce, Adelaide, SA 5000, Australia.; Future Industries Institute, UniSA, Mawson Lakes, SA 5095, Australia., Kral A; University of South Australia, Clinical and Health Science, North Tce, Adelaide, SA 5000, Australia.; Centre for Cancer Biology, S.A. Pathology and University of South Australia, Adelaide, SA 5000, Australia., Prestidge CA; University of South Australia, Clinical and Health Science, North Tce, Adelaide, SA 5000, Australia., Thomas N; University of South Australia, Clinical and Health Science, North Tce, Adelaide, SA 5000, Australia.; The Basil Hetzel Institute for Translational Health Research, Woodville, SA 5011, Australia.; Biofilm Test Facility, Cancer Research Institute, University of South Australia, North Tce, Adelaide, SA 5000, Australia.

Publikováno v: ACS infectious diseases [ACS Infect Dis] 2022 Apr 08; Vol. 8 (4), pp. 841-854. Date of Electronic Publication: 2022 Mar 07.

Protective Liquid Crystal Nanoparticles for Targeted Delivery of PslG: A Biofilm Dispersing Enzyme.

Autor: Thorn CR; Clinical and Health Science, University of South Australia, North Tce, Adelaide, South Australia 5000, Australia.; The Basil Hetzel Institute for Translational Health Research, Woodville, South Australia 5011, Australia.; ARC Centre for Excellence in Bio-Nano Science and Technology, Adelaide, South Australia 5000, Australia.; Biofilm Test Facility, Cancer Research Institute, University of South Australia, North Tce, Adelaide, South Australia 5000, Australia., Raju D; Program in Molecular Medicine, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada., Lacdao I; Program in Molecular Medicine, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada., Gilbert S; Program in Molecular Medicine, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada., Sivarajah P; Program in Molecular Medicine, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada., Howell PL; Program in Molecular Medicine, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada.; Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada., Prestidge CA; Clinical and Health Science, University of South Australia, North Tce, Adelaide, South Australia 5000, Australia.; ARC Centre for Excellence in Bio-Nano Science and Technology, Adelaide, South Australia 5000, Australia., Thomas N; Clinical and Health Science, University of South Australia, North Tce, Adelaide, South Australia 5000, Australia.; The Basil Hetzel Institute for Translational Health Research, Woodville, South Australia 5011, Australia.; ARC Centre for Excellence in Bio-Nano Science and Technology, Adelaide, South Australia 5000, Australia.; Biofilm Test Facility, Cancer Research Institute, University of South Australia, North Tce, Adelaide, South Australia 5000, Australia.

Publikováno v: ACS infectious diseases [ACS Infect Dis] 2021 Aug 13; Vol. 7 (8), pp. 2102-2115. Date of Electronic Publication: 2021 Apr 28.

Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.

Autor: Thorn CR; Clinical and Health Science, University of South Australia, City East Campus, Adelaide, SA, 5000, Australia.; The Basil Hetzel Institute for Translational Health Research, Woodville, SA, 5011, Australia.; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, SA, 5000, Adelaide, Australia., Thomas N; Clinical and Health Science, University of South Australia, City East Campus, Adelaide, SA, 5000, Australia.; The Basil Hetzel Institute for Translational Health Research, Woodville, SA, 5011, Australia.; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, SA, 5000, Adelaide, Australia., Boyd BJ; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, SA, 5000, Adelaide, Australia.; Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC, 3052, Australia., Prestidge CA; Clinical and Health Science, University of South Australia, City East Campus, Adelaide, SA, 5000, Australia. clive.prestidge@unisa.edu.au.; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, SA, 5000, Adelaide, Australia. clive.prestidge@unisa.edu.au.

Publikováno v: Drug delivery and translational research [Drug Deliv Transl Res] 2021 Aug; Vol. 11 (4), pp. 1598-1624. Date of Electronic Publication: 2021 Mar 05.